Search Within

Parisa Momtaz

  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (3)
Groups
  1. Biostatistics Service (7)
  2. Department of Medicine (7)
  3. Epidemiology and Biostatistics (7)
  4. GSK Faculty (7)
  5. Genitourinary Oncology Service (7)
  6. Hematologic Malignancies, Division of (7)

More Groups

People
  1. David Solit (6)
  2. Nikolaus Schultz (5)
  3. David Ilson (4)
  4. David Kelsen (4)
  5. Elizabeth Won (4)
  6. Francisco Sanchez Vega (4)

More People

Years
  1. 2021 (2)
  2. 2020 (1)
  3. 2019 (3)
  4. 2017 (1)
Publications
  1. Journal of Clinical Oncology (2)
  2. Annals of Oncology (1)
  3. Clinical Cancer Research (1)
  4. JCO Precision Oncology (1)
  5. Lancet Oncology (1)
  6. Science Translational Medicine (1)
Publishers
  1. American Society of Clinical Oncology (3)
  2. American Association for Cancer Research (1)
  3. American Association for the Advancement of Science (1)
  4. Elsevier Science, Inc. (1)
  5. Oxford University Press (1)

Results (7)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade
    Journal Article

    Shen, R.; Postow, M. A.; Adamow, M.; Arora, A.; Hannum, M.; Maher, C.; Wong, P.; Curran, M. A.; Hollmann, T. J.; Jia, L.; more...
    Science Translational Medicine (2021)

    Fulltext@MSK | Save
  • Therapeutic implications of detecting MAPK-activating alterations in cutaneous and unknown primary melanomas
    Journal Article

    Shoushtari, A. N.; Chatila, W. K.; Arora, A.; Sanchez-Vega, F.; Kantheti, H. S.; Rojas Zamalloa, J. A.; Krieger, P.; Callahan, M. K.; Betof Warner, A.; Postow, M. A.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial
    Journal Article

    Janjigian, Y. Y.; Maron, S. B.; Chatila, W. K.; Millang, B.; Chavan, S. S.; Alterman, C.; Chou, J. F.; Segal, M. F.; Simmons, M. Z.; Momtaz, P.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S.; Chou, J. F.; Gabler, A. R.; Simmons, M. Z.; Momtaz, P.; Shcherba, M.; Ku, G. Y.; Won, E.; Sanchez-Vega, F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S. B.; Chou, J. F.; Gabler, A.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O-) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA)
    Meeting Abstract

    Janjigian, Y. Y.; Chou, J. F.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; Chong, C. R.; Gerdes, H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • PTEN loss-of-function alterations are associated with intrinsic resistance to BRAF inhibitors in metastatic melanoma
    Journal Article

    Catalanotti, F.; Cheng, D. T.; Shoushtari, A. N.; Johnson, D. B.; Panageas, K. S.; Momtaz, P.; Higham, C.; Won, H. H.; Harding, J. J.; Merghoub, T.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save